Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
3(30%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
4
40%
Ph phase_3
2
20%
Ph phase_1
4
40%

Phase Distribution

4

Early Stage

4

Mid Stage

2

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
4(40.0%)
Phase 2Efficacy & side effects
4(40.0%)
Phase 3Large-scale testing
2(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

10

all time

Status Distribution
Active(6)
Completed(4)

Detailed Status

Completed4
Not yet recruiting3
Recruiting3

Development Timeline

Analytics

Development Status

Total Trials
10
Active
3
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (40.0%)
Phase 24 (40.0%)
Phase 32 (20.0%)

Trials by Status

not_yet_recruiting330%
recruiting330%
completed440%

Recent Activity

3 active trials
Showing 5 of 10
completedphase_2

A Study of MY008211A in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

NCT06050226
not_yet_recruitingphase_2

Study of Safety and Efficacy of MY008211A in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

NCT06134414
recruitingphase_3

Study of Safety and Efficacy of MY008211A in Patients With Residual Anemia Despite Anti-C5 Antibody Treatment

NCT06932471
recruitingphase_3

Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy

NCT06932744
recruitingphase_2

Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria

NCT06933914
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT06050226Phase 2

A Study of MY008211A in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Completed
NCT06134414Phase 2

Study of Safety and Efficacy of MY008211A in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Not Yet Recruiting
NCT06932471Phase 3

Study of Safety and Efficacy of MY008211A in Patients With Residual Anemia Despite Anti-C5 Antibody Treatment

Recruiting
NCT06932744Phase 3

Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy

Recruiting
NCT06933914Phase 2

Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria

Recruiting
NCT06687174Phase 2

Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)

Not Yet Recruiting
NCT06543459Phase 1

To Evaluate the Effect of Single Oral Dose of MY008211A Tablets on QTc Interval in Healthy Subjects

Not Yet Recruiting
NCT05642585Phase 1

A Study of Single-dose MY008211A in Healthy Adults

Completed
NCT05828472Phase 1

A Study of Multiple Ascending Doses MY008211A in Healthy Adults

Completed
NCT05828485Phase 1

Effect of Food on Pharmacokinetics of MY008211A Tablets in Healthy Adult Subjects

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10